GH002
Undisclosed psychiatric/neurological disorders
Preclinical/FormulationEarly-stage development
Key Facts
Indication
Undisclosed psychiatric/neurological disorders
Phase
Preclinical/Formulation
Status
Early-stage development
Company
About GH Research
GH Research is pioneering a new class of psychiatric treatments based on its proprietary mebufotenin (5-MeO-DMT) platform, targeting difficult-to-treat depression subtypes. Early clinical data from its lead inhaled candidate, GH001, show promising remission rates and rapid onset of action within hours. With a cleared regulatory path and a growing intellectual property portfolio, the company is advancing multiple formulations toward late-stage development in major depressive disorders.
View full company profile